News

Palmar-plantar psoriasis? Anti-TNF therapy may be culprit

Publish date: October 4, 2013

 

EXPERT ANALYSIS FROM PERSPECTIVES IN RHEUMATIC DISEASES 2013

The meeting was held by Global Academy for Medical Education. GAME and this news organization are owned by Frontline Medical Communications.

Dr. Gordon reported receiving research support and/or honoraria from AbbVie, Amgen, and other companies. Dr. McInnes reported serving as a speaker, adviser, and/or researcher for Janssen, Roche, and other companies.

Pages

Recommended Reading

Game Changer? First JAK Inhibitor Approved for Rheumatoid Arthritis
Psoriasis Collection
Oral JAK Inhibitor's Clinical Place To Be Determined
Psoriasis Collection
Biologics May Reduce RA Patients' Risk of Early Death
Psoriasis Collection
Subcutaneous Nodules Linked to Cardiovascular Disease Risk in RA
Psoriasis Collection
Anti-TNF drugs don't boost risk of herpes zoster in inflammatory disorders
Psoriasis Collection
All glucocorticoids linked to increased risk of VTE
Psoriasis Collection
Switching anti-TNF drugs of little benefit in psoriatic arthritis
Psoriasis Collection
Preimmunosuppresive hepatitis B screening often goes by the wayside
Psoriasis Collection
Golimumab indication expanded to include ulcerative colitis
Psoriasis Collection
Ustekinumab benefits in PsA sustained through 1 year
Psoriasis Collection